$256.26 1.8%
ALNY Stock Price vs. AI Score
Data gathered: December 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Alnylam Pharmaceuticals (ALNY)

Analysis generated November 5, 2024. Powered by Chat GPT.

Alnylam Pharmaceuticals is a biopharmaceutical company dedicated to transforming the lives of those suffering from genetic disorders. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam leverages its RNA interference (RNAi) therapeutics platform to develop transformative medicines. As of recent years, the company has significant progress in its pipeline, with approved products and multiple late-stage clinical trials.

Read full AI stock Analysis

Stock Alerts - Alnylam Pharmaceuticals (ALNY)

company logo Alnylam Pharmaceuticals | November 28
Insider Alert: Fitzgerald Kevin Joseph is selling shares
company logo Alnylam Pharmaceuticals | November 20
Price is up by 5.1% in the last 24h.
company logo Alnylam Pharmaceuticals | November 15
Price is down by -5.2% in the last 24h.
company logo Alnylam Pharmaceuticals | November 12
Price is down by -5% in the last 24h.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.


Alnylam Pharmaceuticals
Price $256.26
Target Price Sign up
Volume 574,960
Market Cap $32.5B
Year Range $143.31 - $300.55
Dividend Yield 0%
Analyst Rating 74% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24501M303M198M-112M-77M-0.870
Q2 '24660M316M344M-17M64M-0.130
Q1 '24459M265M194M-66M-30M-0.520
Q4 '23408M270M138M-138M-103M-1.100
Q3 '23720M279M441M148M182M1.150

Insider Transactions View All

Fitzgerald Kevin Joseph filed to sell 12,881 shares at $254.5.
November 27 '24
Fitzgerald Kevin Joseph filed to sell 14,202 shares at $250.5.
November 27 '24
Fitzgerald Kevin Joseph filed to sell 12,991 shares at $253.4.
November 27 '24
Fitzgerald Kevin Joseph filed to sell 13,351 shares at $252.
November 27 '24
Fitzgerald Kevin Joseph filed to sell 15,855 shares at $247.8.
November 27 '24

Congress Trading View All

Politician Filing Date Type Size
Joshua Gottheimer
Democrat
Feb 15, 24 Buy $1K - $15K
Joshua Gottheimer
Democrat
Feb 15, 24 Sell $1K - $15K
Joshua Gottheimer
Democrat
Jan 7, 24 Sell $1K - $15K

What is the Market Cap of Alnylam Pharmaceuticals?

The Market Cap of Alnylam Pharmaceuticals is $32.5B.

What is the current stock price of Alnylam Pharmaceuticals?

Currently, the price of one share of Alnylam Pharmaceuticals stock is $256.26.

How can I analyze the ALNY stock price chart for investment decisions?

The ALNY stock price chart above provides a comprehensive visual representation of Alnylam Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Alnylam Pharmaceuticals shares. Our platform offers an up-to-date ALNY stock price chart, along with technical data analysis and alternative data insights.

Does ALNY offer dividends to its shareholders?

As of our latest update, Alnylam Pharmaceuticals (ALNY) does not offer dividends to its shareholders. Investors interested in Alnylam Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Alnylam Pharmaceuticals?

Some of the similar stocks of Alnylam Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.